You are here: Industry Insights > multiple myeloma

News List

FDA committee backs GSK's multiple myeloma drug pharmatimes
July 15, 2020
GlaxoSmithKline's belantamab mafodotin has been backed for approval to treat relapsed/refractory multiple myeloma by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC).
Sanofi secures EC approval for Sarclisa for third-line multiple myeloma pharmaceutical-business-review
June 08, 2020
Sanofi has secured approval from the European Commission (EC) for Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of relapsed and refractory multiple myeloma (MM) in adult patients.
Sanofi gets EC approval for Sarclisa to treat multiple myeloma pharmaceutical-technology
June 04, 2020
Sanofi has received approval from the European Commission (EC) for the use of Sarclisa (isatuximab) with pomalidomide and dexamethasone (pom-dex) to treat adults with relapsed and refractory multiple myeloma (MM).
Janssen's CAR-T shows 100% response rate in multiple myeloma pharmatimes
May 14, 2020
Janssen has unveiled updated results from a mid-stage trial of its CAR-T therapy JNJ-4528, showing high rates of response in patients with relapsed or refractory multiple myeloma.
Janssen Receives FDA Approval of DARZALEX FASPRO with ENHANZE for Multiple Myeloma americanpharmaceuticalreview
May 07, 2020
Halozyme Therapeutics announced its collaborator Janssen Biotech has received approval from the U.S. Food and Drug Administration (FDA) for DARZALEX FASPRO™ (daratumumab hyaluronidase human- fihj).
Kite licences Teneobio’s multiple myeloma targeting antibodies pharmaceutical-technology
April 06, 2020
Gilead unit Kite has signed a licence and collaboration agreement with Teneobio for sole rights to antibodies intended for the treatment of multiple myeloma.
CHMP gives Sanofi positive opinion for Sarclisa pharmatimes
March 30, 2020
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sarclisa (isatuximab).
Empliciti, Revlimid combo falls short in multiple myeloma pharmatimes
March 12, 2020
Bristol-Myers Squibb has revealed that Empliciti (elotuzumab), when added to BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone, has not proved successful in extending the time patients with newly-diagnosed myeloma who were ineligible for ...
Xpovio hits endpoints in Phase III multiple myeloma trial pharmatimes
March 06, 2020
Karyopharm has announced positive top-line results from the randomised Phase III BOSTON study of Xpovio (selinexor).
FDA approves Sarclisa for relapsed refractory multiple myeloma pharmatimes
March 06, 2020
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) for certain adults with relapsed refractory multiple myeloma (RRMM).

Previous page 1 2 3 4 5 6 7 8 9 Next page